GFC Life Science Co., Ltd (KOSDAQ:388610)
South Korea · Delayed Price · Currency is KRW 9,240.00
-290.00 (-3.04%)
At close: Apr 9, 2026
GFC Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Operating Revenue | 17,715 | 16,805 | 13,737 | 13,324 | 11,908 |
Other Revenue | - | - | -0 | -0 | -0 |
| 17,715 | 16,805 | 13,737 | 13,324 | 11,908 | |
Revenue Growth (YoY) | 5.42% | 22.33% | 3.09% | 11.89% | 37.21% |
Cost of Revenue | 9,205 | 8,927 | 7,283 | 7,397 | 8,024 |
Gross Profit | 8,510 | 7,877 | 6,453 | 5,927 | 3,884 |
Selling, General & Admin | 5,261 | 3,882 | 3,709 | 4,117 | 3,458 |
Research & Development | 2,044 | 1,552 | 841 | 967.78 | 694.73 |
Amortization of Goodwill & Intangibles | 59.77 | 47.32 | 75.56 | 72.39 | 62.88 |
Other Operating Expenses | - | - | 40.17 | 32.89 | 29.46 |
Operating Expenses | 8,123 | 6,173 | 5,075 | 5,935 | 4,642 |
Operating Income | 386.26 | 1,705 | 1,379 | -7.37 | -757.9 |
Interest Expense | -298.44 | -1,494 | -218.09 | -205.48 | -219.46 |
Interest & Investment Income | 115.36 | 53.79 | 6.18 | 94.1 | 148.02 |
Earnings From Equity Investments | - | - | - | -323.54 | 217.23 |
Currency Exchange Gain (Loss) | -24.66 | 42.33 | 5.34 | -4.83 | 2.57 |
Other Non Operating Income (Expenses) | 13.78 | -5,995 | 48.91 | -1,907 | 154.12 |
EBT Excluding Unusual Items | 192.3 | -5,689 | 1,221 | -2,355 | -455.42 |
Gain (Loss) on Sale of Investments | -99.22 | 0.26 | 56.46 | 43.9 | 88.57 |
Gain (Loss) on Sale of Assets | 5.31 | -44.53 | 172.58 | - | 835.46 |
Asset Writedown | - | - | -42.72 | -96.86 | - |
Other Unusual Items | - | - | 250 | - | - |
Pretax Income | 98.38 | -5,733 | 1,657 | -2,407 | 468.61 |
Income Tax Expense | -457.04 | 214 | 15.99 | - | 19.91 |
Earnings From Continuing Operations | 555.43 | -5,947 | 1,641 | -2,407 | 448.7 |
Earnings From Discontinued Operations | - | - | -24.41 | -455.09 | - |
Net Income | 555.43 | -5,947 | 1,617 | -2,863 | 448.7 |
Net Income to Common | 555.43 | -5,947 | 1,617 | -2,863 | 448.7 |
Shares Outstanding (Basic) | 5 | 3 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 5 | 3 | 1 | 1 | 1 |
Shares Change (YoY) | 52.03% | 206.48% | 0.01% | 0.02% | 100.00% |
EPS (Basic) | 115.00 | -1872.00 | 1560.00 | -2762.00 | 433.00 |
EPS (Diluted) | 115.00 | -1872.00 | 1560.00 | -2762.00 | 433.00 |
Free Cash Flow | -6,345 | -35.83 | 357.14 | -1,934 | -4,007 |
Free Cash Flow Per Share | -1313.63 | -11.28 | 344.54 | -1865.79 | -3867.17 |
Gross Margin | 48.04% | 46.88% | 46.98% | 44.49% | 32.62% |
Operating Margin | 2.18% | 10.14% | 10.04% | -0.06% | -6.36% |
Profit Margin | 3.14% | -35.39% | 11.77% | -21.48% | 3.77% |
Free Cash Flow Margin | -35.82% | -0.21% | 2.60% | -14.51% | -33.65% |
EBITDA | 2,102 | 3,288 | 2,282 | 755.2 | 36.25 |
EBITDA Margin | 11.87% | 19.57% | 16.61% | 5.67% | 0.30% |
D&A For EBITDA | 1,716 | 1,583 | 903.41 | 762.56 | 794.15 |
EBIT | 386.26 | 1,705 | 1,379 | -7.37 | -757.9 |
EBIT Margin | 2.18% | 10.14% | 10.04% | -0.06% | -6.36% |
Effective Tax Rate | - | - | 0.97% | - | 4.25% |
Advertising Expenses | 259.53 | 157.59 | 342.12 | 277.48 | 387.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.